我們已在上線！進一步了解

iRadimed

IRMD

市值 US$11.3億

88.27 USD

-1.10

1.23%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

88.22

-0.05

0.06%

1天

-1.23%

5天

0.51%

1個月

6.89%

3個月

-9.72%

6個月

-3.93%

今年迄今

-7.57%

1年

16.07%

5年

139.93%

10年

832.1%

關於： iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

員工： 166

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 16.7%

中性 83.3%

負面 0%

IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference

ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference.

IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

iRadimed Q2 Earnings Call Highlights

iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.

iRadimed Q2 Earnings Call Highlights

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026

ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

Zacks Investment Research

iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates

iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.

iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

查看新聞排名

價格圖表採用Lightweight Charts™實作